New research from ESMO 2025 reveals significant survival benefits of intensified androgen blockade over traditional therapies for advanced prostate cancer.
December II 2025
Explore the evolving role of medical oncologists in treating non–muscle invasive bladder cancer with innovative immunotherapy options and trial insights.
Research highlights promising advancements in renal cell carcinoma treatments, focusing on HIF-2α inhibitors and combination therapies for improved patient outcomes.
Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing hospital stays for patients with blood cancers.